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Abstract
Background Standard-of-care (SOC) cancer treatments are
primarily aimed at reducing size and progression of a tumor.
There is a need for successful supplemental anabolic therapies
to combat cancer cachexia in addition to these SOC treatment
modalities. Anabolic interventions, including testosterone and
amino acid supplements, may be beneficial in reducing and/or
reversing muscle wasting in these patient populations.
Methods A 48-year-old Caucasian female with recurrent cer-
vical cancer was scheduled to receive three 21-day cycles of
cisplatin and topetecan chemotherapy. She qualified, con-
sented, and enrolled into a blinded interventional pilot study
where she received daily whey protein (10 g, three times per
day with meals) and a weekly injection of testosterone
enanthate (100 mg intramuscular) before and during the
SOC chemotherapy treatment period. Body composition, se-
rum inflammatory markers, mixed muscle protein synthesis
and breakdown rates, physical function, fatigue, and quality of
life were assessed before and after the intervention period.
Results Body composition, as assessed by an increase in body
weight and lean bodymass and reduction in fat mass; physical
function; fatigue; and quality of life each improved across the
entire intervention period despite general increases in inflam-
matory markers and no improvements in muscle protein turn-
over towards the end of the intervention.
Conclusions Concomitant treatment of oral amino acids and
testosterone may be a viable therapeutic option for fighting
cachexia and improving body composition and quality of
life during chemotherapeutic treatment of recurrent cervical
cancer. These positive outcomes may be attainable over time
despite overall poor inflammatory status.
Keywords Cervical cancer . Testosterone . Amino acids .
Lean body mass . Quality of life . Fatigue
1 Introduction
The rapid loss of fat and lean mass that accompanies cancer
is known as cancer cachexia. The loss of muscle mass can
be profound, sometimes reaching 75 % of the initial level
when the patient has lost 30 % body weight, and is the most
phenotypic feature of cancer cachexia [1, 2]. Cachexia
affects ~50 % of cancer patients, accounts for ~25 % of
cancer deaths, and is one of the principle causes of asthenia,
respiratory complications, poor response to chemotherapy,
increased susceptibility to infection, and poor quality of life
[3–5]. The pathophysiology of cancer cachexia is multifactorial.
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Underlying mechanisms include systemic inflammation, nutri-
ent scavenging by the tumor and tumor derived factors, de-
creased dietary intake, and decreased physical activity.
Common metabolic abnormalities related to cancer cachexia
are altered hormone levels [4, 5], elevated cytokines [3–13],
increased muscle proteolysis, and decreased muscle protein
synthesis [14]. To date, little success has been achieved
toward reversing or preventing cancer cachexia.
The goal of a successful intervention is to reduce skeletal
muscle wasting and improve tumor response to suppressive
therapy, quality of life, general well-being, and the chance
of survival. The response of skeletal muscle to the anabolic
stimulus of amino acids is impaired in cachectic cancer
patients due to alterations in both processes regulating mus-
cle protein balance (i.e., synthesis vs. breakdown), making it
difficult to reach a positive net balance, even acutely. While
cancer patients are, at least to a limited extent, anabolically
responsive to the intake of balanced amino acids [15], their
skeletal muscles exhibit hyperactivation of the muscle proteo-
lytic transcription factor, nuclear factor κB (NFκB), suggesting
that the persistent inflammatory state that accompanies cancer
contributes to dysregulation of muscle protein breakdown.
Combating cancer-related muscle wasting may require combi-
nation therapeutic approaches targeted at improving muscle
anabolism while reducing catabolism. Therefore, we sought
to investigate a targeted nutritional plus hormonal therapy,
attempting to maximize chronic anabolic and anticatabolic
responses in skeletal muscle while minimizing the volume of
the supplement.Whey proteins stimulate food intake and coun-
teract muscle wasting in anorectic weight losing patients [16].
Testosterone also has suppressive actions onmuscle proteolysis
[17] and has been found capable of reducing systemic inflam-
matory cytokines, such as TNF-α and IL-6 in humans [18–20],
and stimulating the anti-inflammatory cytokine IL-10 [21, 22].
Additionally, the use of anabolic steroids such as testosterone to
stimulate protein anabolism in muscle of cancer patients is very
promising and clinically relevant [2, 23–25].
Accordingly, we utilized whey protein supplementation
and testosterone administration as a combination therapeutic
approach in this pilot study on a single patient, with the aim
of testing the feasibility and efficacy of this anabolic inter-
vention to reduce skeletal muscle wasting and improve
quality of life in recurrent cervical cancer patients undergo-
ing chemotherapy. In addition, we sought to determine
potential mechanisms underlying cachexia in this patient
population, including the influence of muscle proteolytic
factors such as TNF-α and NFκB. Specifically, we deter-
mined the effect of nutrition and hormone therapy on lean
body mass, muscle strength, fatigue, quality of life, muscle
protein synthesis and breakdown, inflammatory biomarkers,
and signaling pathways involved in the regulation of muscle
atrophy. Data from this single-blinded case study served as
pilot data prior to initiation of a larger double-blinded
clinical trial aimed at determining whether concomitant
administration of testosterone plus whey protein supplement
can preserve muscle mass, muscle strength, and quality of
life of recurrent cervical cancer patients during the initial
rapid loss of body weight and muscle that often accompa-
nies the reinitiation of chemotherapy. We hypothesize that
the antianorectic and anticachectic effects of whey proteins
and the anabolic and anticatabolic properties of testosterone
will enhance lean muscle mass in patients with recurrent




Inclusion criteria for this intent-to-treat clinical trial were age
between 18 and 59 years, diagnosed with recurrent cervical
carcinoma, weight loss of 5 % or greater in the past 12 months
or a BMI <20 kg/m2, ability to sign consent form (score >23
on the 30-item Mini Mental State Examination, MMSE) and
Eastern Cooperative Oncology Group (ECOG) Performance
Status of 0 to 2 (0 0 fully active, 1 0 reduced activity, 2 0
inactive but ambulatory, 3 0 activity limited to self-care, 4 0
completely disabled, 5 0 dead) [26].Exclusion criteria includ-
ed significant liver, renal, or heart disease; evidence of hepa-
titis as indicated by a threefold increase in of two out of three
liver enzymes; diabetes mellitus or other untreated endocrine
disease; recent (within 3 months) treatment with anabolic
steroids; alcohol or drug abuse; ongoing anticoagulant thera-
py; androgen-secreting tumors of the ovary and adrenal or any
ovarian tumor (e.g., Sertoli-Leydig); polycystic ovary syn-
drome (PCOS); and/or hyperthecosis, nonclassical adrenal
hyperplasia, Cushing's syndrome, glucocorticoid resistance,
pregnancy, hyperprolactinoma, hypothyroidism, lactose intol-
erance, or any other circumstance deemed exclusionary by the
PI or study physician.
A 48-year-old Caucasian female with a past medical
history of squamous cell carcinoma of cervix IIB initially
diagnosed and treated with external radiation therapy (XRT)
and brachytherapy 19 years prior, presented to the oncolo-
gist at the University of Texas Medical Branch (UTMB)
with recurrent cervical cancer. The patient was having
symptoms of gray-colored vaginal discharge along with
some weight loss, but denied any vaginal bleeding or ab-
dominal pain. A biopsy showed well-differentiated kerati-
nized squamous cell carcinoma supporting the diagnosis of
invasive squamous cell carcinoma, but chest X-ray and MRI
of the abdomen/pelvis done at that time showed no evidence
of malignancy. However, the patient was not compliant with
her follow-up and was seen 7 months later when her perfor-
mance status on the Gynecologic Oncology Group/Eastern
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Cooperative Oncology Group (GOG/ECOG) scale was 2
(0inactive but ambulatory) [26]. She was then admitted to
receive three 21-day cycles of cisplatin and topotecan chemo-
therapy. Prior to initiation of her chemotherapy, she consented
and enrolled into a 10-week blinded interventional pilot study
where she received daily whey protein (10 g protein, three
times per day with meals, provided in 12.6 g whey, Optimum
Nutrition, Sunrise, FL) and a weekly injection of testos-
terone enanthate (100 mg intramuscular) before and dur-
ing the standard-of-care (SOC) chemotherapy treatment.
This patient was the first person that was approached by
our medical and research team for inclusion in this study.
2.2 Protocol
The intent-to-treat interventional protocol was scheduled
around the patient's chemotherapy cycles as outlined in
Fig. 1. The 10-week protocol was extended to 11 weeks of
intervention to accommodate the patient's clinical status as
described below. The patient consented within 48 h of
diagnosis with recurrent cervical cancer and reported to the
Institute for Translational Sciences-Clinical Research Center
(ITS-CRC) at the University of Texas Medical Branch
(UTMB) the Sunday before her first scheduled cycle of
chemotherapy later that week. On the days prior to chemo-
therapy, fasting baseline blood was collected and the patient
completed all measures outlined below. The patient was
housed and fed on the ITS-CRC during each week of
chemotherapy and returned home the weeks in between.
While at home, the patient reported to the ITS-CRC weekly
for safety blood draws and to receive an injection of
testosterone, a week supply of oral whey protein supple-
ments, a week supply of questionnaires, and an Actigraph
activity monitor to be worn continuously until the next
visit. Compliance of supplement intake was assessed by
weekly bottle counting and encouraged through conversa-
tions with the patient.
2.3 Body composition measures
Total body and regional body composition was determined
by Dual Energy X-ray Absorptiometry (iDXA, GE Lunar,
Waukesha, WI). Regions of interest were automatically
generated by the Lunar software as described elsewhere
[27]. Where necessary, the automated regions of interest
were adjusted by the same qualified technician that com-
pleted all scans. For instance, the trunk was defined as the
area between the chin, the anterior superior iliac spine, and
the humeral heads.
2.4 Blood measures
Total and free testosterone, estradiol, sex hormone-binding
globulin (SHBG), cholesterol, HDL, LDL, triglycerides, and
cytokines (IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10,
IL-12, IL-13, IFNγ, GM-CSF, and TNFα) were measured in
serum. Hormone assays (testosterone and estradiol) were
measured with a high-throughput continuous random access
immunoassay analyzer (Immulite 2000, Siemens, Deerfield,
IL). Serum cytokines were measured by immunoassay using
a Millipore Human Cytokine-13 Plex Kit (Millipore, Bill-
erica, MA). All other blood measures were measured and
provided by the UTMB Clinical Laboratory.
2.5 Skeletal muscle measures
2.5.1 Mixed muscle fractional synthesis and breakdown
rates (FSR and FBR)
Before beginning the stable isotope study, 10 ml of blood
was drawn to determine concentrations of amino acids,
glucose, hormones, fibrinogen and albumin, cytokines, and
the background enrichment of phenylalanine. A bolus injec-
tion of 30 cc normal saline and a stable isotope tracer of
phenylalanine, ring 13C6-phe (35 μmol/kg body weight),
Fig. 1 Study timeline. The timing of the standard-of-care chemotherapy, blinded interventional treatment, and collection of outcomemeasures are indicated
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was then given marking time 0 of the 60-min study. Blood
samples (5 ml) were drawn at 5, 10, 15, 20, 25, 30, 35, 40,
45, 50, 55, and 60 min after pulse bolus injection from a
hand-heated catheter to provide an arterialized sample. Mus-
cle biopsy samples (~200 mg) were taken at 5 and 60 min
from a single 5-mm incision in the vastus lateralis of the left
limb using a 5-mm Bergström needle. At 30 min, a second
bolus containing 15N-phenylalanine (35 μmol/kg body
weight) was injected. The injection of multiple tracers com-
bined with arterialized and tissue sampling enables calcula-
tion of both the FSR and FBR of mixed muscle protein, as
described in Zhang et al. [28].
2.5.2 Protein signaling
Several signaling cascade proteins involved in the regula-
tion of energy and protein metabolism were measured in
skeletal muscle tissue. Many anabolic responses, including
those to essential amino acids, are mediated through activa-
tion of the mTOR signaling pathway [29], which is modu-
lated through both permissive activation by Akt as well as
through inhibition by AMPKα when cellular energy status
is low. Akt also promotes anabolism through inhibition of
catabolic pathways by blocking of GSK3β and by prevent-
ing the dephosphorylation and translocation of the catabolic
regulators, FoxO1 and FoxO3 [30]. Skeletal muscle myo-
statin signaling through the activin receptor (ActRIIB) neg-
atively regulates cellular turnover by upregulating Smads 2
and 3. Myostatin signaling has been implicated in TNFα-
induced cancer cachexia in rats [31]. Total, and when ap-
propriate, phosphorylated levels of the following proteins
were determined using standard Western Blotting techni-
ques: AktSer473, AMPKαThr172, FoxO1Ser256, FoxO3Ser318/
321, glycogen synthase kinase 3 (GSKSer9), Smad2Ser465/467,
and Smad3Ser423/425.
2.5.3 NF-kB
NFκB activation was measured by detection of p52,
(NFκB1), p65 (RelA), p50, and RelB in nuclear extracts
using an ELISA kit (Active Motif, Carlsbad, CA).
2.6 Physical function measures
2.6.1 Activity
To monitor total physical activity levels and intensities
and to estimate energy expenditure, the patient wore an
Actigraph (GTM1/GT3X) accelerometer (ActiGraph,
LLC) on her ankle during the entire study [32, 33]. Daily
activity data was averaged by week. Data from days with
incomplete data collections (<10,000 counts/day) were
excluded from analyses.
2.6.2 Resting energy expenditure
Expired gases were collected over 15 min of steady state,
and O2 and CO2 concentrations were measured for the
determination of resting energy expenditure (SensorMedics,
Yorba Linda, CA, USA). Substrate oxidation was measured
as described [34].
2.6.3 Muscle strength, power, and fatigue
Isometric and concentric isotonic knee extensor torque was
determined using a Biodex System 3 dynamometer (Biodex
Medical, New York). The testing protocol was designed
with the intent of minimizing patient burden. The patient
was seated with the waist as well as the thigh and ankle of
the nonbiopsied leg secured with straps. A torso strap was
not used in this patient due to the presence of an implanted
venous access port (Port-A-Cath®). Following three warm-
up repetitions at both 25 % and 50 % of the patient's
perceived maximal effort, isometric torque during maximal
voluntary contraction (MVC) was determined. All isometric
efforts were 5 s in duration, with 15 s of rest between efforts.
Following a 2-min rest period, isotonic MVC was similarly
determined following three repetitions at both 25 % and
50 % maximal effort, using a load of 20 % of isometric
MVC, through a range of motion of 75 ° (from 90 ° to 15 °
of flexion; full extension00 ° flexion) using the lateral
femoral epicondyle to align the knee joint axis of rotation
with the dynamometer axis of rotation, with one effort every
5 s. Gravity correction for the weight of the leg was per-
formed by the Biodex Advantage software program. Fol-
lowing 2 min of rest, the patient performed a series of 25
maximal isotonic contractions at 20 % isometric MVC, with
approximately one effort every 2 s. For both isotonic MVC
and fatigue testing, loading during flexion was minimized
using the Biodex software, and the subject was instructed to
let her lower leg passively return to the starting position.
Isometric and isotonic MVC were quantified as the peak
torque and power, respectively. Skeletal muscle fatigue was
evaluated by determining the absolute and relative declines
in average power from the initial three to the final three
isotonic contractions of the fatigue protocol.
2.6.4 Quality of life
Quality of life was assessed by using the following four
questionnaires: (1) Functional Assessment of Cancer
Therapy-G (FACT-G) [35] which contains 27 Likert-type
items divided over four sections (physical well-being, so-
cial/family well-being, emotional well-being, and functional
well-being) and (2) Medical Outcomes Study: 36-Item Short
Form Survey Instrument (MOS-36) [36]. This questionnaire
contains 36 questions to assess physical functioning, role of
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limitations due to physical health, role of limitations due to
emotional problems, energy/fatigue, emotional well-being,
social functioning, pain, and general health. (3) Profile of
Mood States (POMS) [37] which contains 65 questions to
assess six identifiable mood or affective states (tension–
anxiety, depression–dejection, anger–hostility, vigor–activi-
ty, fatigue–inertia, and confusion–bewilderment) and (4)
Multidimensional Fatigue Symptom Inventory-Short Form
(MFSI-SF) addressing 30 questions scored to assess general




There was good compliance with the consumption of the
supplement during the at-home periods. All supplement
bottles were returned empty.
3.2 Body composition measures
Body weight increased from 40 to 43 kg, total lean mass
increased from 26 to 29 kg, and trunk lean mass increased
from 13 to 14 kg between baseline and week 11. Total fat
mass decreased from 14 to 13 kg and trunk fat mass de-
creased from 6 to 5 kg during this period.
3.3 Blood measures
Total and free testosterone and estradiol concentrations in
the serum increased (Table 1). Cholesterol, triglycerides,
HDL, LDL cholesterol, and IGF-1 decreased. Changes in
circulating TNF-α, IL-6, IL-7, IL-8, and Il-10 are shown in
Table 1. All other cytokines measured remained below the
detectable levels of the kit.
3.4 Skeletal muscle measures
3.4.1 Fractional synthesis and breakdown rates (FSR
and FBR)
Fasting mixed muscle FSR was unchanged, but FBR was
higher during the 1-h measurement after the intervention
period compared to baseline (Table 1).
3.4.2 Signaling
Protein expression of skeletal muscle Akt and Smad3 were
higher at week 11 when compared to baseline. There were
no notable changes in the expression of AMPKα, FoxO1,
FoxO3, GSK, or Smad2 (Table 1).
3.4.3 Cytokines
Canonical NFκB activation (nuclear p52 and RelA content)
increased and noncanonical NFκB activation (nuclear p50
and RelB content) decreased (Fig. 2).
3.5 Physical function measures
3.5.1 Activity
Actigraph data indicated low levels of daily activity when
the patient entered the study (26,853±5,175 counts/day
during the first week) when compared to healthy ambulatory
individuals (>250,000 counts/day) as measured by us (un-
published data) and others [38] (Fig. 3). The patient
Table 1 Blood and muscle measures
Baseline Week 11
Blood measures
Total testosterone (ng/dl) 16 1,210
Free testosterone (pg/ml) 0.4 28
Estradiol (pg/ml) <25 43
FSH (mIU/ml) 8.33 0.118
LH (mIU/ml) 0.429 0.280
PRL (ng/ml) 5.44 17.1
SHBG (nmol/l) Not determined 71
IGF-1 (ng/ml) 153 69
Cholesterol (mg/dl) 186 118
Triglycerides (mg/dl) 277 144
HDL cholesterol (mg/dl) 36 15
LDL cholesterol (mg/dl) 105 74
Cortisol (μg/dl) 11.6 5.97
TNF-α (pg/ml) 15.9 12.2
IL-6 (pg/ml) 13.6 21.9
IL-7 (pg/ml) 5.6 6.2
IL-8 (pg/ml) 19.8 26.7
IL-10 (pg/m) 5.8 2.0
Skeletal muscle measures
Skeletal muscle protein kinetics
Fasting FSR (% h−1) 0.07 0.06
Fasting FBR (% h−1) 0.03 0.09
Cell signaling (cytosol)
Akt (arbitrary units) 0.44 2.02
AMPKα (arbitrary units) 1.22 0.89
Phospho-FoxO1 (arbitrary units) 1.36 1.42
Phospho-FoxO3 (arbitrary units) 0.95 0.87
GSK (arbitrary units) 0.74 0.72
Smad2 (arbitrary units) 0.77 0.85
Smad3 (arbitrary units) 1.04 2.71
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increased her daily activity by week 5 (45,200±3,075
counts/day) which was maintained through week 7, but
returned to baseline before the completion of the interven-
tion period (23,459±2,137 counts/day during week 10). The
weekly averages of the peak activity recorded during a
single minute each day are also shown in Fig. 3. Because
the assumption was made that daily counts <10,000 were
due to incomplete data collections and were thus excluded
from further analyses, it remains possible that the data
presented are overestimations of actual activity levels.
3.5.2 Resting energy expenditure
Resting oxygen consumption did not change from baseline
to the end of the intervention (3.60±0.02 vs. 3.65±
0.08 ml kg−1 min−1).
3.5.3 Muscle strength, power and fatigue
Peak isometric torque (Fig. 4a) and peak isotonic power
increased (Fig. 4b). Relative muscle fatigability (final three
contractions of the fatigue protocol compared to the first
three contractions) improved from 20 % at baseline to 5 %
in week 10 (Fig. 4c). Moreover, average peak isotonic
power during the first three contractions of the fatigue
protocol was increased by 40 % after 11 weeks when com-
pared to baseline and average peak isotonic power during the
last three contractions was increased by 70 % (not shown).
3.5.4 Quality of life
Self-reported quality of life improved as indicated by in-
creased scores on the FACT-G and MOS-36, decreased
affective mood scores on the POMS, and reduced fatigue
according to the MSFI-SF (Table 2) [39–42].
3.6 Clinical notes and follow-up
The patient received chemotherapy in weeks 1, 4, and 7 of
the study period. During the study period, the patient
reported to the ITS-CRC with nausea and lack of appetite
in week 3, flulike symptoms in week 5, sleep disturbances
and lack of appetite in week 6, and was admitted to the
hospital in week 9 for nausea, vomiting and fever. At week
10, she again presented with nausea, vomiting, and fever
and was diagnosed with acute hepatitis C, and the patient
was hospitalized. For this reason, her final chemotherapy
session was postponed for a week and the interventional
period was extended to 11 weeks. There were no signs of
virilization at any time.
A large cavitating pelvic mass, identified to be the cervi-
cal carcinoma by CT and MRI of the abdomen/pelvis, had
been stable in size during the previous 5 years. However,
during the first week of chemotherapy, increased inflamma-
tion, fluid, and air were noted, which may have been a local
extension of tumor or an abscess. The possibility of local
extension was not evident in later CT scans during week 9.
The patient had a past history of lymphadenopathy in the
inguinal area; however, these lymph nodes remained stable
in size and distribution, and a biopsy 1 year prior to this
study showed reactive lymphoid tissue but no neoplastic
changes. Repeated chest X-ray and CT scans of the thorax/
abdomen/pelvis did not reveal any obvious distant metastases.
Canonical NF-kB (Nuclear) 























Fig. 2 Skeletal Muscle NF-kB. Expressions of canonical (a) and non-
canonical (b) NF-kB were determined in skeletal muscle tissue obtained



















































Fig. 3 Physical activity. Total daily activity was averaged for each
week during 10 weeks of observation. Peak activities shown are the
means of the highest activity recorded during a single minute within
each day of the week. Data from days with incomplete data collections
(<10,000 counts/day) were excluded from analyses
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There likely was a partial response to chemotherapy as pelvic
mass did not change in size throughout the course of the
chemotherapy, no significant changes in lymphadenopathy
or lymphatic spread of the cancer were noted, and no proven
or definitive metastases were identified during and up to
6 weeks following conclusion of the study.
Monthly follow-ups were conducted by phone after the
final test sessions were completed at week 11. Phone follow-
ups were planned for up to 1 year following completion of
the protocol and consisted of informal conversations with
the patient to inquire about general well-being and quality of
life. Four weeks after discontinuation of the intervention, the
patient entered hospice care. The patient died 10 weeks
following discontinuation of intervention (i.e., ~5 months
from diagnosis/enrollment).
4 Discussion
4.1 Summary of findings
There is a substantial direct benefit in maintaining muscle
function and mass during treatment protocols targeted at
decreasing tumor size. Even successful chemotherapy often
imparts an additional physiological and psychological bur-
den to the patient such as reduced appetite, limited physical
activity, and overall decreased quality of life. Targeted nu-
tritional and/or hormonal therapies in conjunction with anti-
tumor therapy may be beneficial in improving long-term
survival of patients. In this study, we found that concomitant
treatment with oral amino acids and testosterone improved
functional measures such as muscle strength, power, and
fatigue as well as quality of life in a patient undergoing
chemotherapeutic treatment of recurrent cervical cancer.
These improvements were associated with increased body
weight, increased lean body mass, and decreased fat mass,
which occurred despite low daily activity levels and a poor
inflammatory status.
4.2 Nutrition and cancer
Cancer cachexia is a complex phenomenon involving both
tumor-derived factors and systemic factors including hor-
mones and mediators of inflammation. While cancer-
associatedmalnutrition cannot be explained by poor nutritional
intake alone, early nutritional support is paramount to prevent
or retard the downward spiral of malnutrition and to improve
quality of life and chance of survival [5]. Along with strategies
to maintain appetite and adequate food intake, nutrient com-
position must be optimized to maximally induce skeletal mus-
cle anabolism with minimal volume of food intake. Our group
recently reported that skeletal muscle of ovarian cancer
patients is anabolically responsive, albeit with reduced sensi-
tivity, to oral amino acid supplementation, despite the presence
of systemic inflammation [15]. The whey protein supplement
used in the present study provided an over-the-counter ap-
proach that delivered the essential amino acids previously
shown to improve (increase) skeletal muscle protein balance.
In the present case, the patient reportedly enjoyed the whey
protein supplement, which was provided in powdered form to
be mixed with a beverage of the patient's choice. Although the
relative effects of the whey protein supplement and the con-
currently administered testosterone on muscle anabolism and
catabolism cannot be distinguished in the present case, we






























































Fig. 4 Strength and fatigue. Peak isometric torque (a), peak isotonic
power (b), and muscle fatigue (c) were determined before and after the
intervention period
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investigated a panel of signaling pathways previously impli-
cated in muscle anabolism and catabolism. In the present case,
basal Akt and Smad3 were elevated in cytosolic fractions
following the 11-week intervention period, but there were no
changes in AMPKα, Smad2, FoxO1, FoxO3, or GSK. Nota-
bly, these responses to the therapeutic regimen only reflect the
fasting state under which the muscle biopsies were taken. As
accrual or loss of skeletal muscle mass is dependent on the
integrated net balance between muscle protein synthesis and
breakdown over time, complementary studies under fasting
and fed conditions will be necessary to determine which sig-
naling pathways play an important role.
4.3 Hormones and inflammation
Elevation of skeletal muscle IGF-1 production with testos-
terone therapy and subsequent suppression of protein
breakdown has indicated that testosterone exerts anticata-
bolic properties [17]. Testosterone has been shown to reduce
inflammatory cytokines such as TNF-α, IL-6, and IL-1B in
humans [18–20]. Androgen treatment has been shown to
interfere with canonical [43], but not noncanonical [44], NF-
kB signaling in prostate cancer cell lines and repress IL-6
expression [45]. However, the role of NF-kB signaling in
the regulation of skeletal muscle protein is complex and not
well understood [46]. The leading explanation for the in-
crease in canonical NF-kB proteins (p50/RelA) in the pres-
ent study is the increased inflammatory burden of the patient
towards the end of her chemotherapy treatment period, in
part aggravated by acute hepatitis C. Activation of transcrip-
tion factors like NF-kB by cytokines, such as TNF-α and
proteolysis-inducing factor (PIF), is a first and important
step for NF-kB-induced muscle proteolysis and apoptosis
[47–51]. However, as we did not measure all possible
Table 2 Quality of life







Physical well-being 13 27 0 28
Social/family well-being 27 25 0 28
Emotional well-being 6 14 0 24
Functional well-being 10 13 0 28
Total 55 78 0 108 68±18
MOS-36 [40]
Physical functioning 10 20 0 100
Role of limitations
(physical health)
0 0 0 100
Role of limitations
(emotional)
0 0 0 100
Energy/vitality 35 15 0 100
Emotional well-being 40 35 0 100
Social functioning 13 38 0 100
Pain 23 48 0 100
General health 25 35 0 100 63±20
POMS [41]
Tension–anxiety 18 13 36 0
Depression 36 23 60 0
Anger–hostility 12 17 48 0
Vigor 15 10 0 32
Fatigue 10 10 28 0
Confusion 12 13 28 0
TMD 73 66 +200 −32 32±29
MFSI-SF [42]
General 15 11 24 0
Physical 7 9 24 0
Emotional 17 8 24 0
Mental 7 9 24 0
Vigor 5 8 0 24
Total 41 29 +96 −24 14±16
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activators of NF-kB signaling, it remains unclear what the
direct driving factors were for the observed changes in NF-
kB signaling. We noted no increases in circulating inflam-
matory signals, such as TNF-α or IL-1, at the time of
biopsy. In contrast to the catabolic role sometimes ascribed
to NF-kB, another model of skeletal muscle NF-kB signal-
ing suggests a role of the canonical pathway (p50/RelA) in
stimulating myogenesis, while the noncanonical pathway
(p52/RelB) may be subsequently involved in mitochondrial
biogenesis within the differentiated myotubes [52]. Activa-
tion of p50/RelA increases production of IL-6, a potential
important regulator during skeletal muscle differentiation
[53]. This cytokine is acutely upregulated in skeletal muscle
following exercise where it may play a physiological role
(myokine) in skeletal muscle anabolism [54]. In contrast,
chronic systemic elevation of IL-6 is often found in catabol-
ic disease states such as cancer cachexia, and elevations of
IL-6 in late stage cachectic patients have been reported in
the absence of elevated TNF-α [55]. Increases in serum IL-6
during cisplatin-based chemotherapy do not necessarily cor-
relate to tumor size in cervical cancer [56]. However, we
should acknowledge that the cytokines measured mediate
numerous other responses and thus further studies are nec-
essary to verify and further elucidate the role of NF-KB in
human cancer patients. The data from the single patient
reported here and the clinical complications that presented
near the final data collection period are insufficient to un-
equivocally support any one of the possible roles of NF-kB
in regulation of muscle mass and thus completion of addi-
tional subjects receiving SOC treatment either with or without
anabolic support will be needed to clarify the mechanisms most
likely involved. The diagnosis of acute hepatitis C towards the
conclusion of our study timeframe is likely to be a major
contributing factor to the increased inflammatory state and
may be responsible for the acute measurements of decreased
serum IGF-1 concentrations [57] and increased protein break-
down despite maintenance of LBM and muscle strength mea-
sured across the entire treatment period. Furthermore, while
testosterone is considered to be protective against inflamma-
tion, more subjects are needed in the ongoing double-blinded
placebo-controlled study to ascertain whether testosterone ad-
ministration can demonstrate anti-inflammatory benefits in this
patient population.
4.4 Goal of intervention
Successful nutrition/hormone therapymust demonstrate effec-
tiveness in maintaining or improving functional outcomes
without negatively affecting ongoing tumor-suppressive ther-
apies. We elected to use SOC male hormone replacement
doses in order to treat this female patient with supraphysio-
logic testosterone doses. We selected this treatment paradigm
because this was a terminal patient, and our goal was to
maximize the hormonal response. We understand that if tes-
tosterone is considered a therapy in women without a terminal
condition, additional consideration should be given to the
dose and duration of testosterone used to minimize virilization
and other side effects such as the significant lowering of the
patients HDL with the testosterone injections. Tumor size, as
assessed by CT and pelvic examinations, did not change
during treatment in this patient. Although not observed in this
patient, in response to the combination therapy of whey pro-
tein and testosterone, it is important to monitor patients for
sudden unforeseen changes in tumor size. However, incidence
of this risk is expected to be minimal in the context of the
testosterone intervention, since the expression of androgen
receptor is generally much lower in cervical carcinomas when
compared to normal epithelium [58]. Similarly, we do not
know whether, or how, the supplemental therapy affects pa-
tient survival. Up to 30 % of cervical patients do not survive
longer than 6 months following diagnosis and the onset of
cisplatin + topetecan based-therapy [59].
5 Conclusion
The goal of a supplemental intervention is ultimately to im-
prove quality of life, performance status, and chance of survival
of the patient beyond that which is achieved with standard of
care chemotherapy alone. Concomitant treatment of oral amino
acids and testosterone may be a viable therapeutic option for
fighting cachexia and improving body composition and quality
of life during chemotherapeutic treatment of recurrent cervical
cancer. In the case study we present here, we utilized a combi-
nation therapy approach of oral whey protein plus testosterone
to improve muscle mass and quality of life during chemother-
apy in a patient with recurrent cervical cancer. Clearly, a larger
cohort is needed to determine whether such supplemental treat-
ment approaches are efficacious over the long-term in improv-
ing body composition, physical function, quality of life, and
cancer survival of cachectic patients when compared to stan-
dard of care alone. A double-blinded, placebo-controlled inter-
ventional study is in progress (NCT00878995).
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